|
|
|
|
| LEADER |
00000cam a2200000 i 4500 |
| 001 |
EBSCO_ocn841170363 |
| 003 |
OCoLC |
| 005 |
20231017213018.0 |
| 006 |
m o d |
| 007 |
cr ||||||||||| |
| 008 |
121227s2013 nyu ob 001 0 eng |
| 010 |
|
|
|a 2020677655
|
| 040 |
|
|
|a DLC
|b eng
|e rda
|c DLC
|d N$T
|d YDXCP
|d OCLCF
|d EBLCP
|d ICA
|d AGLDB
|d VTS
|d AU@
|d STF
|d M8D
|d K6U
|d E7B
|d OCLCO
|d OCLCQ
|
| 019 |
|
|
|a 923663441
|
| 020 |
|
|
|a 9781624179532
|q ebook
|
| 020 |
|
|
|a 1624179533
|
| 020 |
|
|
|z 9781624179525
|
| 020 |
|
|
|z 1624179525
|
| 029 |
1 |
|
|a NZ1
|b 15021825
|
| 029 |
1 |
|
|a DEBSZ
|b 481272763
|
| 029 |
1 |
|
|a DEBBG
|b BV042795222
|
| 035 |
|
|
|a (OCoLC)841170363
|z (OCoLC)923663441
|
| 042 |
|
|
|a pcc
|
| 050 |
0 |
0 |
|a RM666.V33
|
| 072 |
|
7 |
|a MED
|x 093000
|2 bisacsh
|
| 072 |
|
7 |
|a MED
|x 105020
|2 bisacsh
|
| 082 |
0 |
0 |
|a 615.7/84
|2 23
|
| 049 |
|
|
|a UAMI
|
| 245 |
0 |
0 |
|a Valproic acid :
|b pharmacology, mechanisms of action and clinical implications /
|c Alexis Boucher, editor.
|
| 264 |
|
1 |
|a New York :
|b Nova Biomedical,
|c [2013]
|
| 300 |
|
|
|a 1 online resource.
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 490 |
1 |
|
|a Pharmacology-research, safety testing and regulation
|
| 504 |
|
|
|a Includes bibliographical references and index.
|
| 588 |
|
|
|a Description based on print version record.
|
| 505 |
0 |
|
|a VALPROIC ACID ; VALPROIC ACID; Contents ; Preface ; Novel Applications of the Anticonvulsant DrugValproic Acid in Cancer Therapeutics ; Abstract ; Abbreviations and Explanations ; 1. The Involvement of VPA in Cancer and the Associated Signaling Pathways ; 2. VPA Acts as a HDAC Inhibitor; 3. VPA Acts as a Notch Regulator ; 3.1. VPA Acts as a Positive Notch Regulator ; 3.1.1. Neuroendocrine Tumors (NETs) ; 3.1.2. Non-neuroendocrine Tumors (nonNETs) ; 3.2. VPA Acts as a Negative Notch Regulator ; 4. VPA Acts as a GPCR Regulator and Enhances Receptor-TargetedChemotherapeutics.
|
| 505 |
8 |
|
|a 4.1. VPA Acts as a GPCR Regulator 4.1.1. Melatonin MT1 Receptor ; 4.1.2. Chemokine Receptor (CXCR) ; 4.1.3. Somatostatin Receptors (SSTRs) ; 4.1.4. VPA-mediated Other Receptors ; 4.2. VPA Enhances GPCR-targeted Anti-cancer Therapeutics ; 5. The Application of VPA in Combination with Other Anti-cancer Agents ; 5.1. Neuroblastoma ; 5.2. Breast Cancer ; 5.3. Glioblastoma ; 5.4. Glioma ; 5.5. Prostate Cancer ; 5.6. Malignant Pleural Mesothelioma (MPM); 5.7. Colonrectal Cancer ; 5.8. Leukemia and Lymphoma ; 5.8.1. AML ; 5.8.2. ALL ; 5.9. Melanoma ; 5.10. Cervical Cancer.
|
| 505 |
8 |
|
|a 5.11. Renal Cell Cancer (RCC) 5.12. Thyroid Cancer ; 5.13. Carcinoid ; 5.14. Hepatocellular Cancer (HCC) ; 5.15. Myeloma ; 5.16. Esophageal Squamous Cell Cancer (ESCC) ; 5.17. Cholangiocarcinoma ; 5.18. Lung Cancer ; 5.19. Pancreatic Cancer ; Conclusion ; References ; Valproic Acid and Epilepsy:From Basic Research to Clinical Findings ; Abstract ; Introduction ; VPA and Brain Disorders ; Neuropsychiatric Disorders ; VPA and Epilepsy ; Seizures and Epilepsy Definitions ; Basic Study Findings ; Clinical Study Findings ; VPA Mechanisms of Action in Epilepsy ; GABAergic and Glutamatergic System.
|
| 505 |
8 |
|
|a HDAC Inhibitor and Neuropeptide Y Neuroprotective and Antiapoptotic Effects of VPA; VPA and Neurogenesis ; Conclusion ; Disclaimer ; Acknowledgments ; References ; Use of Fish Models in Fetal Valproate Syndrome Study ; Abstract ; Introduction ; Japanese Medaka as a Model to Study Fetal Valproate Syndrome ; Conclusion ; Acknowledgments ; References ; Valproic Acid, Genetics, and Autism: How EpimutationAlters Disease Susceptibility ; Abstract ; Introduction ; DNA Flexibility Promotes Instability ; Autism and Mutation Susceptibility ; Conclusion ; References.
|
| 505 |
8 |
|
|a Determination of Acute Lethal and Chronic Lethal Dose Thresholds of Valproic Acid Using 3D Spheroids Constructed from the Immortal Human Hepatocyte Cell Line HepG2/C3A Abstract ; Introduction; Materials and Methods ; Standard 2D Cell Culture Conditions; 3D Spheroid Culture Conditions Preparation of Spheroids Using AggreWell Plates ; Spheroid Culture in ProtoTissue Bioreactors ; Microscopy and Planimetry ; Drug Treatment ; ATP Assay; Adenylate Kinase Assay for Cell Viability ; Protein Determination ; Glucose Determination ; Results ; Discussion ; Molecular Basis for VPA Toxicity.
|
| 590 |
|
|
|a eBooks on EBSCOhost
|b EBSCO eBook Subscription Academic Collection - Worldwide
|
| 650 |
|
0 |
|a Valproic acid.
|
| 650 |
|
2 |
|a Valproic Acid
|
| 650 |
|
6 |
|a Acide valproïque.
|
| 650 |
|
7 |
|a MEDICAL
|x Pain Medicine.
|2 bisacsh
|
| 650 |
|
7 |
|a MEDICAL
|x Psychiatry
|x Psychopharmacology.
|2 bisacsh
|
| 650 |
|
7 |
|a Valproic acid.
|2 fast
|0 (OCoLC)fst01163858
|
| 700 |
1 |
|
|a Boucher, Alexis,
|e editor.
|
| 776 |
0 |
8 |
|i Print version:
|t Valproic acid
|d New York : Nova Biomedical, c2013.
|z 9781624179525
|w (DLC) 2012956452
|
| 830 |
|
0 |
|a Pharmacology-research, safety testing, and regulation series.
|
| 856 |
4 |
0 |
|u https://ebsco.uam.elogim.com/login.aspx?direct=true&scope=site&db=nlebk&AN=561597
|z Texto completo
|
| 938 |
|
|
|a YBP Library Services
|b YANK
|n 10393026
|
| 938 |
|
|
|a EBSCOhost
|b EBSC
|n 561597
|
| 938 |
|
|
|a ebrary
|b EBRY
|n ebr10676422
|
| 938 |
|
|
|a ProQuest Ebook Central
|b EBLB
|n EBL3020259
|
| 994 |
|
|
|a 92
|b IZTAP
|
